H. pylori (HP) infection affects >60% of the world’s population and was found
to be associated
with numerous gastrointestinal disorders, e.g. peptic ulcer disease, gastric
adenocarcinoma, gastric MALT lymphoma, dyspepsia, and anemia.
|Treatment of Helicobacter Pylori Associated Disorders|
Current treatments are based on “Triple Therapy”, which involves 10-14 days
of treatment with a combination of at least 2 antibacterials and an acid-suppressing
agent (usually PPI). Eradication rates, using this regimen, have been dropping over
time. This has been attributed to an increasing H. pylori resistance to the
antibiotics used; Poor patient compliance with the multi daily drugs used in
leads to a dramatic drop in the cure rate.
VECTA is currently exploring to develop VECAM together with Amoxicillin as a short term,
novel anti-HP treatment.
Employing the robust gastric acid inhibition of VECAM as of first treatment
for utilization of essential host-parasite interaction mechanisms, we suggest that
the combination of VECAM with Amoxicillin will suffice for its eradication and shall
lead to excellent compliance.